Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction: PPARγ sumoylation-mediated lipid accumulation in lung cancer.
|
30858930 |
2019 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It implies that the therapeutic effect of lipo-ATRA in lung cancer was exhibited by ameliorating the TIG3 expression and by suppressing the expression of PPARγ.
|
31300983 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Keith and colleagues have performed a careful study, which utilized the PPARγ nuclear receptor agonist, pioglitazone, a common type II diabetes agent, in subjects at risk for lung carcinoma.
|
31537582 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings thus provide the basis for the rational and personalized use of PPARγ agonists in combination with EGFR TKIs in lung cancer patients.
|
29378193 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides an important insight of future translational and clinical research into targeting PPARγ regulation of lipid metabolism in lung cancer patients accompanying type 2 diabetes.
|
29137280 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gain and loss-of-function studies were performed to investigate the effects of microRNA-130b, peroxisome proliferator-activated receptor γ (PPARγ) or vascular endothelial growth factor-A (VEGF-A) on biological functions of lung cancer cells using in vitro and in vivo approaches.
|
27364335 |
2016 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, this study demonstrates COX-2 induction and subsequent COX-2-dependent activation of PPARγ as a hitherto unknown mechanism by which lovastatin lactone induces human lung cancer cell death.
|
26863638 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that ligand-mediated sumoylation of PPARγ plays an important role in lung cancer pathogenesis by modulating prostaglandin metabolism.
|
26244663 |
2015 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor γ (PPARγ) is another member of the nuclear receptor family which induces apoptosis in lung cancer.
|
22843091 |
2012 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The in vivo results were confirmed in the human lung cancer cells, which showed that PGZ induced lung cancer cell apoptosis through up-regulating nuclear PPARγ expression, inducing PPARγ transcriptional activity and increasing the levels of PPARγ ligands in NNK-treated cells.
|
22463586 |
2012 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
SPI1, FLI1, FOS, ETS2, EGR1 and PPARG were defined as candidate genes for squamous lung cancer by the transcriptome network analysis method.
|
21922129 |
2012 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinically, use of thiazolidinediones, which are pharmacological activators of PPARγ is associated with a lower risk of developing lung cancer.
|
22145026 |
2011 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings may also reveal the possibility of using the level of endogenous PPARγ ligands and the activities of PPARγ or PPARα as tumor markers for lung cancer.
|
20081051 |
2010 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that activation of peroxisome proliferator-activated receptor γ (PPAR-γ) inhibits transforming growth factor β (TGF-β)-induced EMT in lung cancer cells and prevents metastasis by antagonizing Smad3 function.
|
21159608 |
2010 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that PPAR-gamma polymorphisms and their interaction with smoking may contribute to the etiology of lung cancer.
|
18187557 |
2008 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies indicate that PPARgamma is a critical target for prostacyclin-mediated lung cancer chemoprevention and may also have therapeutic activity.
|
19138979 |
2008 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will focus on the role of two members of this family (estrogen receptors and PPARgamma) in the initiation and progression of lung cancer.
|
16199155 |
2005 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
|
15866424 |
2005 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we explore approaches to maximizing the proapoptotic effects of PPARgamma on lung cancer cell lines.
|
15899809 |
2005 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed that the PPARgamma ligands PGJ2 and ciglitazone inhibit the growth and induce the apoptosis of several human lung carcinoma cell lines, whereas the PPARalpha agonist WY14643 has little effect.
|
15041706 |
2004 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent work has also suggested a role for PPARgamma in cell cycle control and/or differentiation of other cell types including breast and lung cancer cells.
|
11205925 |
2001 |